Effects of Diazepam on Hippocampal Blood Flow in People at Clinical High Risk for

Psychosis

Nicholas R. Livingston, MSc⁺; Amanda Kiemes, PhD⁺
Knight, MSc¹; Paulina B. Lukow, PhD^{4,5}; Luke A. Jelen,
Dima, MD⁵; Maria Antonietta Nettis, PhD⁵; Cecilia Ca
Fernando Zelaya, PhD⁷; Thomas Spencer, PhD^{5,8}; A ; Gabriel A. Devenyi, PhD^{2,2}; Samuel

MD¹; Thomas Reilly, MD⁶; Aikaterin

setta, MD⁵; Tyler Agyekum, BSc^{2,3};

lrea De Micheli, PhD^{5,8}; Paolo Fusar-l

ams, PhD⁷; Philip McGuire, PhD⁶; Alic

a Modinos, PhD¹ 1 Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King's College

London, OK
²Departmen

Bepartment of Psychiatry, McGill Officersity, Montreal, QC, Canada
³Cerebral Imaging Centre, Douglas Mental Health University Institute

Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, QC, Canada 4

Institute or Cognitive Neuroscience, Oniversity College London, OK
Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College
Landes Lill

London, OK
⁶Departmen

Knight, MSc⁺
Dima, MD⁵; I
Fernando Zel
PhD^{5,8,9,10}; A
Egerton, PhD
¹Department of
²Department of
³Cerebral Imagi
³Cerebral Imagi
London, UK
Epeartment of
⁶Department of
⁷Department of
⁷Department of
⁷ ; Paulina B. Lukow, PhD^{-,-}; Luke A. Jelen, MD⁻
Maria Antonietta Nettis, PhD⁵; Cecilia Casetta
laya, PhD⁷; Thomas Spencer, PhD^{5,8}; Andrea D
nthony A. Grace, PhD¹¹; Steve C.R. Williams, F
⁵; M. Mallar Chakravar ; Thomas Reilly, MD°

, MD⁵; Tyler Agyekun

e Micheli, PhD^{5,8}; Pa

²hD⁷; Philip McGuire,

dinos, PhD^{1,12}

alology, and Neuroscience

, Montreal, QC, Canada

, and Neuroscience, King's C ,

n, BSc^{2,3};

olo Fusar-P

, PhD⁶; Alice

.

, King's College

,

Scollege

Londor Dima, MD⁵
Fernando Z
PhD^{5,8,9,10};
Egerton, Pł
¹Department
London, UK
³Cerebral Ima
³Cerebral Ima
⁵Department
⁵Department
⁵Department
⁶Department
⁷Department
⁷Department
⁷Department
⁷Department
⁷ ; Maria Antonietta Nettis, PhD⁵
Zelaya, PhD⁷; Thomas Spencer, F
Anthony A. Grace, PhD¹¹; Steve
nD⁵; M. Mallar Chakravarty, PhE
of Psychological Medicine, Institute of
Of Psychiatry, McGill University, Mor
aging Cen ; Cecilia Casetta, MD⁵
PhD^{5,8}; Andrea De Mic
PhD^{5,8}; Gemma Modinos
D^{2,3}; Gemma Modinos
of Psychiatry, Psychology,
treal, QC, Canada
University Institute, Mont
Illege London, UK
chiatry, Psychology, and Neur
IK
Brit ; Tyler Agyekum, BSc^{2,3};
cheli, PhD^{5,8}; Paolo Fusar
Philip McGuire, PhD⁶; Al
, PhD^{1,12}
and Neuroscience, King's Co
real, QC, Canada
leuroscience, King's College
roscience, King's College Lone
Maudsley (SLaM) NHS Fo Fernando Zelaya, PhD'
PhD^{5,8,9,10,}; Anthony A.
Egerton, PhD⁵; M. Mall
¹Department of Psychologi
¹Department of Psychiatry,
³Cerebral Imaging Centre, I
⁴Institute of Cognitive Neur
⁵Department of Psychiatry,
7 ; Thomas Spencer, PhD^{5,6}; Andrea De Micheli, PhD^{5,6}; Paolo Fusar-Poli,
Grace, PhD¹¹; Steve C.R. Williams, PhD⁷; Philip McGuire, PhD⁶; Alice
lar Chakravarty, PhD^{2,3}; Gemma Modinos, PhD^{1,12}
cal Medicine, Instit PhD^{5,8,9,120}; Anthony A. Grace, PhD²⁺; Steve C.R. Williams, PhD⁷
Egerton, PhD⁵; M. Mallar Chakravarty, PhD^{2,3}; Gemma Modino
¹Department of Psychiological Medicine, Institute of Psychiatry, Psychology
London, UK ; Philip McGuire, PhD°
s, PhD^{1,12}
v, and Neuroscience, King's
htreal, QC, Canada
Neuroscience, King's Colleg
uroscience, King's College
d Maudsley (SLaM) NHS Fo
sity Munich, Germany
ittsburgh, Pittsburgh, PA, ;
college
ge
London,
undatio
USA Egerton, PhD⁵
¹Department of F
London, UK
³Cerebral Imagin
⁴Institute of Cographer
⁵Department of F
⁵Department of F
⁵Department of IUK
⁸Department of IUK
⁸Department of IUK
⁸Department of I¹⁰Departme ; M. Mallar Chakravarty, PhD^{2,2}; Gemma Modinos, PhD^{2,22}
Psychological Medicine, Institute of Psychiatry, Psychology, and Neuro
Psychiatry, McGill University, Montreal, QC, Canada
g Centre, Douglas Mental Health Univers Department of Esychiatry, Oniversity of Oxford, OK
7 Department of Neuroimaging, Institute of Psychiatry, Psychology, and Neuroscience, King's College London,
'''

UK 8 Outreach and Support in South-London (OASIS) service, South London and Maudsley (SLaM) NHS Foundation

Trust, UK
⁹Departm

Department of Brain and Behavioural Sciences, University of Pavia, Italy
⁰Department of Braskistas and Brasketherman Undustry Medicine Unive "Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University Munich, Germany
¹¹Departments of Naussasianas, Durchistor and Durchalamy University of Pittchurch, Pittchurch, 1

 11 Departments of Neuroscience, Psychiatry and Psychology, University of Pittsburgh, Pittsburgh, PA, USA

 12 MRC Centre for Neurodevelopmental Disorders, King's College London, UK

,
,
,
, Nicholas.livingsto
Short/running title: Diaze
Keywords: benzodiazepin
TE: This preprint reports new rese Short/running title : Diazepam effects
Keywords : benzodiazepine ; GABA; ne
TE: This preprint reports new research that has not $\frac{1}{2}$

Short-running title: The section of the Networds: benzodiazepine; GABA; neuroimaging; CBF; schizophrenia; experiment
TE: This preprint reports new research that has not been certified by peer review and should not be use
T

Abstract (244 words)
Background: Elevated
risk for psychosis (CF
central to the pathop
during adolescence c
we examined whether
Methods: Using a ran
individuals were asse
diazepam (5 mg) and
measured using 3D p

risk for psychosis (CHR-P). Preclinical evidence suggests that hippocampal hyperactivity is
central to the pathophysiology of psychosis, and that prophylactic treatment with diazepam
during adolescence can prevent the deve risk for psychoal evidence suggests that hipperturn in precliming a control to the pathophylsiology of psychosis, and that prophylactic treatment with diazepam
during adolescence can prevent the development of psychosis-re channed to the pathophylactic prophetic treatment of psychosis-relevant phenotypes. Here
we examined whether diazepam normalises hippocampal perfusion in CHR-P individuals.
Methods: Using a randomised, double-blind, placeb during a mormalises hippocampal perfusion in CHR-P individuals.

Methods: Using a randomised, double-blind, placebo-controlled, crossover design, 24 CHR-P

individuals were assessed with MRI on two occasions, once followin Methods: Using a randomised, double-blind, placebo-controlled, crossover design, 24 CH
individuals were assessed with MRI on two occasions, once following a single oral dose
diazepam (5 mg) and once following placebo. Regi methods: Using a randomised, double-blind, placebo-controlled, crossover design, 24 CHR-
Individuals were assessed with MRI on two occasions, once following a single oral dose of
diazepam (5 mg) and once following placebo. diazepam (5 mg) and once following placebo. Regional cerebral blood flow (rCBF) was
measured using 3D pseudo-continuous arterial spin labelling and sampled in native space
using participant-specific hippocampus/subfield ma measured using 3D pseudo-continuous arterial spin labelling and sampled in native space
using participant-specific hippocampus/subfield masks (CA1, subiculum, CA4/dentate gyrus).
Twenty-one healthy controls (HC) were scann using participant-specific hippocampus/subfield masks (CA1, subiculum, CA4/dentate gyrus).
Twenty-one healthy controls (HC) were scanned using the same acquisition sequence, but
without administration of diazepam or place Twenty-one healthy controls (HC) were scanned using the same acquisition sequence, but
without administration of diazepam or placebo. Mixed-design ANCOVAs and linear mixed-
effects models were used to examine the effects

without administration of diazepam or placebo. Mixed-design ANCOVAs and linear mixed-
effects models were used to examine the effects of group (CHR-P placebo/diazepam vs. HC)
and condition (CHR-P diazepam vs. placebo) on p_{FDR} =0.225). and condition (CHR-P diazepam vs. placebo) on rCBF in the hippocampus as a whole and by
subfield.
Results: Under the placebo condition, CHR-P individuals (mean[±SD] age: 24.1[±4.8] years,
15F) showed significantly eleva subfield.
 Results: Under the placebo condition, CHR-P individuals (mean[±SD] age: 24.1[±4.8] years,

15F) showed significantly elevated rCBF compared to HC (mean[±SD] age: 26.5[±5.1] years,

11F) in the hippocampus (F(Results:
Results:
15F) sho
11F) in tl
Following
significan
P_{FDR}=0.22 Results: Under the placebo condition, CHR-P individuals (mean[±SD] age: 24.1(±4.8) years,
15F) showed significantly elevated rCBF compared to HC (mean[±SD] age: 26.5[±5.1] years,
11F) in the hippocampus (F(1,36)=8.2, $p_{\$ 11F) in the hippocampus (F(1,36)=8.2, p_{fDR} =0.004) and across its subfields (all p_{fDR} <0.001).
Following diazepam, rCBF in the hippocampus (and subfields, all p_{fDR} <0.001) was
significantly reduced (t(69)=-5.1, p_{f 111 f in the implocating (F(1,36)=8.2, pFDR=0.004) and across its subfields (all pFDR<0.001) was
significantly reduced (f(69)=-5.1, p_{FDR}<0.001) and normalised to HC levels (F(1,41)=0.3,
p_{FDR}=0.225). Following diazepani, rCBF in the implocatinguis (and subfields, all pFDRS0.001) was
significantly reduced ($t(69)$ =-5.1, p_{FDR} <0.001) and normalised to HC levels ($F(1,41)$ =0.3,
 p_{FDR} =0.225). p_{FDR} =0.225).
 p_{FDR} =0.225). $p_{FDR} = 0.225$

Conclusions: Diazepam can normalise implocampal hyperperfusion in CHR-P individuals,
consistent with evidence implicating medial temporal GABAergic dysfunction in the
pathophysiology of psychosis. construction with evidence implicating media temporal GABA existence in the constraints of the constraints of \mathcal{L} p athophysiology of psychosis. The psychosis is p

Transformations in our un
disorders drove a marked
in individuals at clinical hi
of psychosis onset may be
minimal influence on trans
single preventive interven
underlying the CHR-P |
interventions to prevent p Transformations in our understanding of the nature, actively, and early course of plystand
disorders drove a marked re-orientation of mental health services toward early intervention
in individuals at clinical high-risk fo In individuals at clinical high-risk for psychosis (CHR-P), raising the prospect that prevention
of psychosis onset may be a realistic goal¹². Despite this progress, current treatments have a
minimal influence on transit In individuals at continuity process for process, current treatments have a
of psychosis onset may be a realistic goal^{1,2}. Despite this progress, current treatments have a
minimal influence on transition to psychosis^{3,4} of psychosis onset may be a realistic goal^{***}. Despite this progress, current treatments have a
minimal influence on transition to psychosis^{3.4}, and there is no robust evidence to favour any
single preventive intervent

minimal influence on transition to psychosis^{3,3}, and there is no robust evidence to favour any
single preventive intervention over another^{5,6}. A better understanding of the neurobiology
underlying the CHR-P phenotype i single preventive intervention over another²⁵. A better understanding of the neurobiology
underlying the CHR-P phenotype is critical for the much-needed development of
interventions to prevent psychosis onset.
Postmortem Postmortem, preclinical, and clinical neuroimaging evidence suggests that hippocampal
abnormalities are central to the pathophysiology of psychosis^{7.8}, thus representing a
potential therapeutic target. Hippocampal dysfu Postmortem, preclinical, and clinical neabnormalities are central to the pathopotential therapeutic target. Hippocampa
a disruption in neural excitatory/inhil
interneuron dysfunction^{9–13}. This wou
hyperactive¹⁴, and e Fariheim in de la fariheim de la fa
Fariheim de la fariheim de la fari abnormalities are central to the pathophysiology of psychosis^{7,8}, thus representing a
potential therapeutic target. Hippocampal dysfunction in psychosis is proposed to arise from
a disruption in neural excitatory/inhibi abnormalities are central to the pathophysiology of psychosis⁷¹⁵, thus representing a
potential therapeutic target. Hippocampal dysfunction in psychosis is proposed to arise from
a disruption in neural excitatory/inhibit a disruption in neural excitatory/inhibitory balance driven by GABAergic inhibitory
interneuron dysfunction^{9–13}. This would render the hippocampus dysrhythmic and
hyperactive¹⁴, and excessive glutamatergic output^{15–1} interneuron dysfunction⁹⁻¹³. This would render the hippocampus dysrhythmic and
hyperactive¹⁴, and excessive glutamatergic output¹⁵⁻¹⁸ from the hippocampus to the
striatum, amygdala, and prefrontal cortex may underli interneuron dysfunction⁹²². This would render the hippocampus dysrhythmic and
hyperactive¹⁴, and excessive glutamatergic output^{15–18} from the hippocampus to the
striatum, amygdala, and prefrontal cortex may underli hyperactive²⁴, and excessive glutamatergic output⁴² ²⁶ from the hippocampus to the striatum, amygdala, and prefrontal cortex may underlie the development of positive, negative, and cognitive symptoms, respectively¹⁹ regative, and cognitive symptoms, respectively¹⁹. Preclinical findings in the well-validated
methylazoxymethanol acetate (MAM) rodent model of neurodevelopmental disruption^{20–22}
indicate that a loss of hippocampal par negative, and cognitive symptoms, respectively⁵². Preclinical findings in the well-validated
methylazoxymethanol acetate (MAM) rodent model of neurodevelopmental disruption^{20–22}
indicate that a loss of hippocampal parv methylazoxymethanol acetate (MAM) rodent model of neurodevelopmental disruption²⁰
indicate that a loss of hippocampal parvalbumin-expressing (PV+) inhibitory interneurons²³
leads to hippocampal hyperactivity^{24,25}, as indicate that a loss of hippocampal parvalbumin-expressing (PV+) inhibitory interneurons²⁵
leads to hippocampal hyperactivity^{24,25}, as measured with electrophysiology. Rodent models
have also shown that selective reduc leads to hippocampal hyperactivity^{24,25}, as measured with electrophysiology. Rodent models
have also shown that selective reduction in PV mRNA expression²⁶ or knock-out of PV+
interneuron expression^{24,25} are each suf have also shown that selective reduction in PV mRNA expression²⁵ or knock-out of PV+
interneuron expression^{24,25} are each sufficient to induce hippocampal hyperactivity. In MAM-
treated rats, hippocampal hyperactivity interneuron expression 4π 25 are each sufficient to induce hippocampal hyperactivity. In MAM-
treated rats, hippocampal hyperactivity leads to striatal hyperdopaminergia²¹, which is a
4 treated rats, hippocampal hyperactivity leads to striatal hyperdopaminergia²¹, which is a
4
4

core neurobiological feature of positive symptoms in schizophrenia²⁷. This hippocampal
hyperactivity can in turn be normalised by hippocampal chemical inactivation^{22,27}, or by
pharmacologically facilitating hippocampal hyperactivity can in turn be normalised by hippocampal chemical inactivation²², or by
pharmacologically facilitating hippocampal GABA signalling through direct infusion of either
a nonselective (the benzodiazepine midazo pharmacologically facilitating interesting the state of the announced and and an and an and an and all steel tive daba signal provides all osteric modulator (PAM)^{28,29}. Furthermore, chronic administration of the benzodia a nonselective (the benzodiazepine midazolam)²⁸ or an α5-subunit selective GABA_A receptor
positive allosteric modulator (PAM)^{28,29}. Furthermore, chronic administration of the
benzodiazepine diazepam during the perip

positive allosteric modulator (PAM)^{28,29}. Furthermore, chronic administration of the
benzodiazepine diazepam during the peripubertal period prevented the development of
psychosis-relevant features in adulthood^{30–32}, hi psychosis-relevant features in adulthood^{30–32}, highlighting the prophylactic potential of
GABA-enhancing compounds for psychosis.
In individuals at CHR-P, hippocampal hyperactivity has been observed *in vivo*^{33–37}, wh psychosis-relevant features in adulthood²⁰¹²², highlighting the prophylactic potential of
GABA-enhancing compounds for psychosis.
In individuals at CHR-P, hippocampal hyperactivity has been observed *in vivo*^{33–37}, w In individuals at CHR-P, hippocampal hypera
a result of neurovascular coupling – is assoc
or volume (rCBF or rCBV), revealed using an
magnetic resonance imaging (MRI), respo
individuals has been associated with ele-
capaci laceric hesi In individuals at CHR-P, hippocampal hyperactivity has been observed *in vivo*²², which – as
a result of neurovascular coupling – is associated with increased regional cerebral blood flow
or volume (rCBF or rCBV), reveal a resultion or volume (rCBF or rCBV), revealed using arterial spin labelling (ASL) or gadolinium-contrast
magnetic resonance imaging (MRI), respectively. Elevated hippocampal rCBF in CHR-P
individuals has been associated w magnetic resonance imaging (MRI), respectively. Elevated hippocampal rCBF in CHR-P
individuals has been associated with elevated striatal pre-synaptic dopamine synthesis
capacity³⁸ and elevated medial prefrontal cortex G individuals has been associated with elevated striatal pre-synaptic dopamine synthesis
capacity³⁸ and elevated medial prefrontal cortex GABA concentrations³⁹. Baseline elevated
hippocampal rCBF or rCBV was also found capacity³⁸ and elevated medial prefrontal cortex GABA concentrations³⁹. Baseline elevated
hippocampal rCBF or rCBV was also found to predict higher positive and negative symptoms
severity³³, poor functioning^{33,38}, capacity³⁸ and elevated medial prefrontal cortex GABA concentrations³⁷. Baseline elevated
hippocampal rCBF or rCBV was also found to predict higher positive and negative symptoms
severity³³, poor functioning^{33,38}, severity³³, poor functioning^{33,38}, and transition to psychosis^{33,34,39}, and to normalise in those
individuals who remit from the CHR-P state³⁵. Within the hippocampus, hyperactivity is
proposed to originate in the severity³³, poor functioning^{33,336}, and transition to psychosis^{23,33}, and to normalise in those
individuals who remit from the CHR-P state³⁵. Within the hippocampus, hyperactivity is
proposed to originate in the CA individuals who remit from the CHR-P state²⁷. Within the hippocampus, hyperactivity is
proposed to originate in the CA1 subfield and then extend to the subiculum and
beyond^{33,34,37}. Hence, hippocampal rCBF may be a bio beyond^{33,34,37}. Hence, hippocampal rCBF may be a biomarker for symptom severity and
psychosis onset in CHR-P individuals, which preclinical evidence suggests may be prevented
by pharmacological enhancement of hippocampa beyond^{33,34,37}. Hence, hippocampal rCBF may be a biomarker for symptom severity and
psychosis onset in CHR-P individuals, which preclinical evidence suggests may be prevented
by pharmacological enhancement of hippocampal by pharmacological enhancement of hippocampal GABA levels^{30–32}.
55 by pharmacological enhancement of hippocampal GABA levels^{30–32}.
Alternation of the state o

Individuals with a GABA-enhancing drug may prevent or delay the onset of psychosis, proof-
of-concept mechanistic evidence is first required to elucidate its effects on hippocampal
hyperactivity. While prior positron or xe single dose of diazepam vs. placebo on ASL-derived rCBF in the hippocampus and its of-concept mechanism entertion mechanism is concepted to entertion in important to elements of the
demonstrated global reductions in CBF under an acute non-sedating dose of a
benzodiazepine in healthy controls⁴⁰⁻⁴³, incl demonstrated global reductions in CBF under an acute non-sedating dose of a
benzodiazepine in healthy controls⁴⁰⁻⁴³, including reductions in temporal lobe rCBF⁴⁰, no
studies have investigated the hippocampus specifical benzodiazepine in healthy controls⁴⁰⁻⁴³, including reductions in temporal lobe rCBF⁴⁰, no
studies have investigated the hippocampus specifically. Furthermore, no studies have been
conducted in CHR-P individuals, in who benzodiazepine in healthy controls^{40–43}, including reductions in temporal lobe rCBF⁴⁶, no
studies have investigated the hippocampus specifically. Furthermore, no studies have been
conducted in CHR-P individuals, in who conducted in CHR-P individuals, in whom the effects of a benzodiazepine challenge on
hippocampal rCBF may differ from that in healthy controls given the proposed GABAergic
dysfunction in this population¹⁴. Hence, the pr hippocampal rCBF may differ from that in healthy controls given the proposed GABAergic
dysfunction in this population¹⁴. Hence, the present study compared the acute effects of a
single dose of diazepam vs. placebo on ASL dysfunction in this population¹⁴. Hence, the present study compared the acute effects of a
single dose of diazepam vs. placebo on ASL-derived rCBF in the hippocampus and its
subfields in 24 CHR-P individuals. To determin dystunction in this population". Hence, the present study compared the acute effects of a
single dose of diazepam vs. placebo on ASL-derived rCBF in the hippocampus and its
subfields in 24 CHR-P individuals. To determine b subfields in 24 CHR-P individuals. To determine baseline alterations in the CHR-P group, rCBF
measures from CHR-P individuals under placebo were compared to those from 21 healthy
controls (HC). We hypothesised that compare measures from CHR-P individuals under placebo were compared to those from 21 healthy
controls (HC). We hypothesised that compared to HC, CHR-P individuals under placebo
would show increased rCBF in the hippocampus and its measure from the material and protect that compared to the material ander placebo
would show increased rCBF in the hippocampus and its subfields, which would be most
apparent in the CA1 subregion^{33,34}. Secondly, consiste examined the CA1 subregion^{33,34}. Secondly, consistent with the preclinical evidence²⁹, we hypothesised that a single dose of diazepam would reduce hippocampal rCBF in CHR-P individuals compared to placebo, and that thi apparent in the CA1 subregion^{33,34}. Secondly, consistent with the preclinical evidence²⁹, we
hypothesised that a single dose of diazepam would reduce hippocampal rCBF in CHR-P
individuals compared to placebo, and that apparent in the CA1 subregion^{33,34}. Secondly, consistent with the preclinical evidence²³, we
hypothesised that a single dose of diazepam would reduce hippocampal rCBF in CHR-P
individuals compared to placebo, and tha hypotial individuals compared to placebo, and that this would be observed across all subfields due to similar levels of GABA_A receptor expression^{44,45}. For completeness, supplementary analyses examined broader effects ismilar levels of GABA_A receptor expression^{44,45}. For completeness, supplementary analyses
examined broader effects of diazepam on voxel-wise grey matter (GM) rCBF, as well as
associations between baseline levels of sy s milar levels of GABA_A receptor expression^{45,45}. For completeness, supplementary analyses
examined broader effects of diazepam on voxel-wise grey matter (GM) rCBF, as well as
associations between baseline levels of examined broader effects of the state and specifically provided associations between baseline levels of symptoms/functioning and diazepam-induced hippocampal rCBF changes in CHR-P individuals. hippocampal rCBF changes in CHR-P individuals.

6

hippocampal rCBF changes in CHR-P individuals.

Methods and Materials (1209 words)

Participants

CHR-P individuals

Support in South London), an early-intervention service within the South London and
Maudsley NHS Foundation Trust, UK⁴⁶. CHR-P criteria was assessed using the Comprehensive
Assessment of At-Risk Mental State (CAARMS)⁴⁷ Maudsley NHS Foundation Trust, UK⁴⁶. CHR-P criteria was assessed using the Comprehensive
Assessment of At-Risk Mental State (CAARMS)⁴⁷. All individuals were required to be
experiencing current attenuated psychotic symp Maudsley NHS Foundation Trust, UK⁴⁶. CHR-P criteria was assessed using the Comprehensive
Assessment of At-Risk Mental State (CAARMS)⁴⁷. All individuals were required to be
experiencing current attenuated psychotic symp Assessment of At-Risk Mental State (CAARMS)". All individuals were required to be
experiencing current attenuated psychotic symptoms, defined as having a severity and
frequency score of 3 or above for an ongoing symptom on experiency score of 3 or above for an ongoing symptom on either P1 (unusual thought
content), P2 (non-bizarre ideas), P3 (perceptual abnormalities), or P4 (disorganised speech)
of the CAARMS. Exclusion criteria included pr frequency score of 3 or above for an ongoing symptom on emits to change formed an open
content), P2 (non-bizarre ideas), P3 (perceptual abnormalities), or P4 (disorganised speech)
of the CAARMS. Exclusion criteria included contribution of the CAARMS. Exclusion criteria included previous/current exposure to antipsychotics,
current exposure to psychotropic medications with GABAergic or glutamatergic action
(except for antidepressants), pregnan

HC individuals

current exposure to psychotropic medications with GABAergic or glutamatergic action
(except for antidepressants), pregnancy/breastfeeding, IQ<70, and any contraindication to
MRI scanning.
In order to validate hippocampal h (except for antidepressants), pregnancy/breastfeeding, IQ<70, and any contraindication to
MRI scanning.
HC individuals
In order to validate hippocampal hyperactivity in this sample of CHR-P individuals, we
utilised data f (except for antial propertion, pregnancy, presentation, presentation, and any contribution to the NRI scanning.

In order to validate hippocampal hyperactivity in this sample of CHR-P individuals, we

utilised data from 21 Man Framing.
HC individuals
In order to va
utilised data fr
same scanning
were reanalyse
dataset recru
publication⁴⁸.
Study design a In order to valid in the superior in the same of this sample of CHR-P in this material hyperature.
In this same scanning sequences and acquisition parameters as the CHR-P sample (below). HC data
were reanalysed with the sa utilised data from 21 HC from a previous study⁴⁶, scanned on the same MRI scanner with the
same scanning sequences and acquisition parameters as the CHR-P sample (below). HC data
were reanalysed with the same preprocessi same scanning sequences and acquisition parameters and actual stample (below). The same
were reanalysed with the same preprocessing steps as the CHR-P data. Details on the HC
dataset recruitment and inclusion/exclusion cri were recruitment and inclusion/exclusion criteria are described in the original
publication⁴⁸.
Study design and procedure publication⁴⁸.
Study design and procedure
7

publication"[.]
Study design a
^{Study} design a Study design and procedure

Committee and was carried out at King's College London. All participants provided written
informed consent. Using a randomised, double-blind, placebo-controlled, crossover design,
the 24 CHR-P participants underwent two M Entert and was carried out at King's College Committee provided, crossover design,
the 24 CHR-P participants underwent two MRI sessions, once under an acute oral dose of
diazepam (5 mg; generic) and once under oral placebo information consent that the using a randomised, the and the sessions, once under an acute oral dose of
diazepam (5 mg; generic) and once under oral placebo (50 mg ascorbic acid; Crescent
Pharma Ltd, Hampshire, UK), with a the 24 CHR-P participants underto the 24 CHR-P particle of diazepam (5 mg; generic) and once under oral placebo (50 mg ascorbic acid; Crescent
Pharma Ltd, Hampshire, UK), with a minimum 3-week washout period between visits Pharma Ltd, Hampshire, UK), with a minimum 3-week washout period between visits. Prior
to the first scanning visit and randomisation, during an assessment visit demographic
information, basic medical history, and clinical/ Frame Information, the first scanning visit and randomisation, during an assessment visit demographic
information, basic medical history, and clinical/cognitive assessments were collected,
including the CAARMS⁴⁷, Global information, basic medical history, and clinical/cognitive assessments were collected,
including the CAARMS⁴⁷, Global Functioning Social and Role scales⁴⁹, Hamilton Anxiety and
Depression scales^{50,51}, Wechsler Adult including the CAARMS⁴⁷, Global Functioning Social and Role scales⁴⁹, Hamilton Anxiety and
Depression scales⁵⁰⁵¹, Wechsler Adult Intelligence Scale III⁵², and the Trail Making Test A &
B⁵³. At each scanning visit including the CAARMS"', Global Functioning Social and Role scales"", Hamilton Anxiety and
Depression scales⁵⁰⁵¹, Wechsler Adult Intelligence Scale III⁵², and the Trail Making Test A &
B⁵³. At each scanning visit, the Depression scales²⁰⁰², Wechsler Adult Intelligence Scale III¹⁶, and the Trail Making Test A &
B⁵³. At each scanning visit, the capsule (with diazepam or placebo) was administered 60
minutes prior to MRI scanning, so B". At each scanning visit, the capsule (with diazepam or placebo) was administered 60
minutes prior to MRI scanning, so that the MRI session coincided with peak diazepam
plasma levels⁵⁴. Full details of the clinical/cog

MRI acquisition

mann levels⁵⁴. Full details of the clinical/cognitive assessments and scanning visit
procedures (including randomisation and maintenance of blinding) can be found in the
Supplementary Methods.
MRI acquisition
MRI scannin plasma levels". Full details of the clinical/cognitive assessments and scanning visit
procedures (including randomisation and maintenance of blinding) can be found in the
Supplementary Methods.
MRI acquisition
MRI scanning Supplementary Methods.

MRI acquisition

MRI scanning for all participants was conducted at the Centre for Neuroimaging Sciences,

King's College London, using a General Electric MR750 3.0T MR scanner with an 8-channel

he MRI acquisition
MRI scanning for all parti
King's College London, us
head coil. rCBF was me
TE=11.088 ms, TR=4,923
time was 6 minutes and 8
the Supplementary Methc
masks, a T1-weighted King's College London, using a General Electric MR750 3.0T MR scanner with an 8-channel
head coil. rCBF was measured using a 3D pseudo-continuous ASL sequence (pcASL;
TE=11.088 ms, TR=4,923 ms, FoV=240) as used in previous Figure 2.1.088 ms, TR=4,923 ms, FoV=240) as used in previous CHR-P studies^{35,36,48}. Total scanner was 6 minutes and 8 seconds. Further details of the pcASL sequence can be found in the Supplementary Methods. For image re TE=11.088 ms, TR=4,923 ms, FoV=240) as used in previous CHR-P studies^{35,36,48}. Total scan
time was 6 minutes and 8 seconds. Further details of the pcASL sequence can be found in
the Supplementary Methods. For image regi TE=11.088 ms, TR=4,923 ms, FoV=240) as used in previous CHR-P studies^{35,35},⁴⁹. Total scand
time was 6 minutes and 8 seconds. Further details of the pcASL sequence can be found in
the Supplementary Methods. For image r the Supplementary Methods. For image registration and generation of hippocampal/subfield
masks, a T1-weighted SPGR (TE=3.02 ms, TR=7.31 ms, TI=400 ms, flip angle=11°,
8 masks, a T1-weighted SPGR (TE=3.02 ms, TR=7.31 ms, TI=400 ms, flip angle=11°, $\frac{1}{8}$ $\frac{1}{\sqrt{2}}$ masks, a T1-weighted SPGR (TE=3.02 ms, Ti=3.02 ms, Ti=3.02 ms, Ti=3.02 ms, Ti=400 ms, $\frac{1}{\sqrt{2}}$

Generation of hippocampal/subfield and total GM masks

matrix=256x256, FoV=270, in-plane resolution=1.05x1.05 mm²
slices) and T2-weighted FRFSE (TE=64.9 ms, TR=4380 ms, flip
FoV=240, in-plane resolution=1.25x0.94 mm², slice thickness=
acquired.
Image processing
Generatio angle=111°, matrix=320x256,

=2 mm, 72 slices) image was

and correcting bias field

us/subfield masks (whole

ted for each participant from

he MAGeT Brain (multiple FoV=240, in-plane resolution=1.25x0.94 mm², slice thickness=2 mm, 72 slices) image was
acquired.
Image processing
Generation of hippocampal/subfield and total GM masks
Structural scans were preprocessed, including denoi FoV=240, in-plane resolution=1.25x0.94 mm²
acquired.
Image processing
Generation of hippocampal/subfield and total
Structural scans were preprocessed, inclu
inhomogeneities using the N3 algorithr
hippocampus, subiculum, GM masks
ding denoising, and correcting bias field
 n^{55} . Hippocampus/subfield masks (whole
vere then generated for each participant from
can by using the MAGeT Brain (multiple
nt brains) toolbox^{56–58} (Figure 1). This Image pro
Generatio
Structural
inhomoge
hippocam
their pre
automatic
automatic
Alzheimer France processing
 Generation of hipp

Structural scans

inhomogeneities

hippocampus, sub

their preprocesse

automatically gen

has been validat

Alzheimer's disea

toolboxes includir Inhomogeneities using the N3 algorithm⁵⁵. Hippocampus/subfield masks (whole
hippocampus, subiculum, CA1, and CA4/DG) were then generated for each participant from
their preprocessed structural T1 SPGR scan by using the inhomogeneities using the N3 algorithm⁻⁷. Hippocampus/subtield masks (whole
hippocampus, subiculum, CA1, and CA4/DG) were then generated for each participant from
their preprocessed structural T1 SPGR scan by using the M metrically entirely substanting and catego in the substantial to comparison their preprocessed structural T1 SPGR scan by using the MAGeT Brain (multiple automatically generated templates of different brains) toolbox⁵⁶⁻⁵⁸ automatically generated templates of different brains) toolbox⁵⁶⁻⁵⁸ (Figure 1). This toolbox
has been validated to generate accurate hippocampus and subfield segmentations in
Alzheimer's disease and psychosis cohorts, wi automatically generated templates of different brains) toolbox⁵⁶⁻⁵⁶ (Figure 1). This toolbox
has been validated to generate accurate hippocampus and subfield segmentations in
Alzheimer's disease and psychosis cohorts, Alzheimer's disease and psychosis cohorts, with greater accuracy than other available
toolboxes including Freesurfer 7 and FSL FIRST⁵⁷. This is largely due to an intermediate
template step which allows incorporating the Malay and the season interest and proposed and FSL FIRST⁵⁷. This is largely due to an intermediate template step which allows incorporating the neuroanatomical variability of the dataset into the segmentation of each par toolboxes including Freesurter 7 and FSL FIRST". This is largely due to an intermediate
template step which allows incorporating the neuroanatomical variability of the dataset into
the segmentation of each participant, red the segmentation of each participant, reducing registration and resampling errors, thereby
yielding more accurate results. Hippocampal subfields CA2/3 were not included due to the
limitations in reliably sampling these sma metaling more accurate results. Hippocampal subfields CA2/3 were not included due to the
limitations in reliably sampling these smaller regions within the spatial resolution and low
signal-to-noise ratio constraints of ASL Figure 1.1 Initiations in reliably sampling these smaller regions within the spatial resolution and low
signal-to-noise ratio constraints of ASL⁵⁹. Total GM masks were made through binarising GM
segmentations.
ASL sampli signal-to-noise ratio constraints of ASL⁵⁹. Total GM masks were made through binarising GM
segmentations.
AS*L sampling*
Masks were registered and resampled to the individuals respective CBF map using
ANTs/2.5.0 (https:/

ASL sampling

signal-to-noise ratio constraints of ASL". Total GM masks were made through binarising GM
segmentations.
AS*L sampling*
Masks were registered and resampled to the individuals respective CBF map using
ANTs/2.5.0 (https://gi ASL sampling
Masks were re
ANTs/2.5.0 (<u>htt</u>) ANTs/2.5.0 (https://github.com/ANTsX/ANTs), and the mean rCBF value was extracted per A

ROI per hemisphere in native space using minc-toolkit-v2/1.9.18 tools (https://bic-

Region-of-interest (ROI) analysis

Therefore, a group/condition*hemisphere term was included to investigate whether the magnetary 1934 - 3 supplementary Methods).

Region-of-interest (ROI) analysis

All ROI analyses were completed in R 4.2.2 (https:

assessed the effect of group (CHR-P placebo/diazep

vs. placebo) on rCBF per ROI (total GM, All Rosessed the effect of group (CHR-P placebo/diazepam vs. HC) or condition (CHR-P diazepam

Summer ws. placebo) on rCBF per ROI (total GM, whole hippocampus, CA1, subiculum, CA4/DG;

Figure 2C). Each model included rCBF assessed by an analysis of the same region in the same subject reflects a repeated measurement.

Figure 2C). Each model included rCBF values per hemisphere, on the basis that bilateral

sampling of the same region in the Figure 2C). Each model included rCBF values per hemisphere, on the basis that bilateral
sampling of the same region in the same subject reflects a repeated measurement.
Therefore, a group/condition*hemisphere term was incl Figure 2C).
Therefore, a group/condition*hemisphere term was included to investigate whether the
effect of group or condition on rCBF significantly differed within a region based on
hemisphere. Significance was set at pFDR

Therefore, a group/condition*hemisphere term was included to investigate whether the
effect of group or condition on rCBF significantly differed within a region based on
hemisphere. Significance was set at pFDR<0.05, after Effect of group or condition on rCBF significantly differed within a region based on
hemisphere. Significance was set at pFDR<0.05, after correcting for multiple comparisons
using the Benjamini-Hochberg method⁶⁰.
CHR-P effects. Significance was set at pFDR<0.05, after correcting for multiple comparisons
using the Benjamini-Hochberg method⁶⁰.
CHR-P placebo vs. HC. Two-way mixed analysis of covariance (ANCOVA; package stats/3.6.2)
models re.

Significance was set at a product of the main significance (ANCOVA; package stats/3.6.2)

models assessed baseline rCBF differences in CHR-P individuals compared to HC, covarying

for age, sex, and global CBF. Supplem using the Benjamini-Hochberg method⁸⁰.
 CHR-P placebo vs. HC. Two-way mixed an

models assessed baseline rCBF difference

for age, sex, and global CBF. Supplen

demographic characteristics which differe

impact rCBF (d

CHR-P placebo vs. HC. Two-way inised analysis of covariance (ANCOVA; package stats/3.6.2)
models assessed baseline rCBF differences in CHR-P individuals compared to HC, covarying
for age, sex, and global CBF. Supplementar models assessed as a global CBF. Supplementary analyses were performed covarying for
demographic characteristics which differed between groups (IQ, ethnicity) or are known to
impact rCBF (daily current cigarette use⁶¹ a demographic characteristics which differed between groups (IQ, ethnicity) or are known to impact rCBF (daily current cigarette use 61 and ROI grey matter volume⁶²).
CHR-P diazepam vs. CHR-P placebo. Diazepam-induced demographic characteristics which different values of \mathcal{C} . The compared to characteristic different values of the placebo were assessed using linear mixed-effects models (package $\text{Im}4/1.1-34$) with participant ID impact rCBF (daily current cigarette use⁴² and ROI grey matter volume⁴⁴).
 CHR-P diazepam vs. CHR-P placebo. Diazepam-induced changes in

placebo were assessed using linear mixed-effects models (package

participant Placebo were assessed using linear mixed-effects models (package lme4/1.1-34) with
participant ID as a random effect (intercept). Given the within-subject design and
widespread expression of GABA_A receptors with benzodia participant ID as a random effect (intercept). Given the within-subject design and
widespread expression of GABA_A receptors with benzodiazepine binding sites across the
brain⁴⁴, global CBF was not included as a covari provides
pread expression of GABA_A receptors with benzodiazepine binding sites across the
brain⁴⁴, global CBF was not included as a covariate. Supplementary analyses investigated
10 brain⁴⁴, global CBF was not included as a covariate. Supplementary analyses investigated
10 brain⁴⁴, global CBF was not included as a covariate. Supplementary analyses investigated
10
10

potential confounding effects of global CBF, sex, order of scan conditions, and number of
days between scans on the results.

CHR-P diazepam vs. HC. To examine whether diazepam would normalise hippocampal rCBF in CHR-P individuals to HC levels, two-way mixed ANCOVA models were run covarying for in CHR-P individuals to HC levels, two-way mixed ANCOVA models were run covarying for
age, sex, and global CBF. $\frac{1}{2}$

Exploratory/supplementary analyses

Voxel-wise grey matter rCBF analysis

For completeness, we explore the effects of diazepam vs. placebo on vote on vocal-
The two-level modelbuild toolkit The two-level modelbuild toolkit
(github.com/CoBrALab/optimized_ants MultivariateTemplateConstruction) was used to generate a study-specific anatomical template (Figure 1; Supplementary Methods). CBF maps were resampled into common-space and smoothed with a 6 mm FWHM Gaussian kernel. A voxelwise linear mixed-effects model (R-3.5.1, RMINC-1.5.2.2, lme4 1.1-21) was used to investigate the effect of condition (CHR-P diazepam vs. placebo) on rCBF, with participant ID as random effect and masked using a study-average GM mask. Significance was set at pFDR<0.05. The above procedure was repeated for investigating voxel-wise group differences in rCBF between CHR-P placebo and HC, using the one-level model template build and running a voxel-wise linear model, covarying for global CBF, age, and sex, and masked using a study-average GM mask.

masked using a study-average GM mask. Clinical characteristics and hippocampal rCBF change

Supplementary analyses using Pearson's correlations assessed whether baseline clinical
characteristics (positive symptom severity, negative symptom severity, cognitive functioning, social functioning, role functioning, anxiety symptom severity, depression symptom severity) social functioning, role functioning, anxiety symptom severity, depression symptom severity)

were associated with the mean percent change in bilateral hippocampal rCBF under
diazepam vs. placebo (see Supplementary Methods for further details on composition of clinical characteristics scores). Potential confounding effects of global CBF on these results were explored using partial Pearson's correlations. Outlier detection was performed on significant correlations using Cook's distance. Significance was set at p <0.05, and multiple comparison corrections were not performed as these analyses were exploratory. comparison corrections were not performed as these analyses were exploratory.

Results (625 words)
Participant demographic and clinical characteristics are detailed in Table 1. CHR-P individuals had a significantly lower IQ compared to HC and differed in terms of ethnicity. This was had a significantly lower \mathbb{R} compared to the and differed in terms of entirely. This was \mathbb{R}^n driven by an above-average mean IQ^{vo} and a higher proportion of white ethnicity in the HC
group.
group. $rac{1}{2}$

|
| ROI analysis

CHR-P placebo vs. HC

 ρ_{FDR} =0.014) in CHR-P individuals under placebo (62.1 \pm 14.9) compared to HC (54.3 \pm 10.9; p_{FDR}=0.014) in CHR-P individuals under placebo (62.1±14.9) compared to HC (54.3±10.9;
Figure 2A). Figure 2A).
Hippocampus and subfield rCBF. After controlling for global CBF, age, and sex, CHR-P

participants in the placebo condition had significantly higher rCBF compared to HC (12.8%) in the hippocampus ($F(1,41)=24.7$, $p_{FDR}<0.001$), which did not differ between hemispheres $(F(1,44)=1.6, p_{FDR}=0.217;$ Figure 2B). Similar results were found for all subfields: CA1 (group: $F(1,41)$ =25.8, p_{FDR} <0.001; group*hemisphere: $F(1,44)$ =1.1, p_{FDR} =0.364; Figure 2D), subiculum (group: $F(1,41)=25.7$, $p_{FDR}<0.001$; group*hemisphere: $F(1,44)=1.2$, $p_{FDR}=0.274$; Figure 2E), and **CA4/DG** (group: $F(1,41)=20.4$, $p_{FDR} < 0.001$; group*hemisphere: $F(1,44)=3.2$, $p=0.082$; Figure 2F). These results did not change when adding in additional covariates (IQ, ethnicity, current daily cigarette use, ROI grey matter volume; Supplementary Table 1).

current daily cigarette use, ROI grey matter volume; Supplementary Table 1). CHR-P diazepam vs. CHR-P placebo

Global CBF. In CHR-P participants, mean CBF in total brain grey matter was significantly lower
(t(23)=-4.3, p_{FDR} <0.001) under diazepam (56.3±12.7) compared to placebo (62.1±14.9; (*t*(23)=-4.3, _{*P*FDR}<0.001) under diazepam (56.3±12.7) compared to placebo (62.1±14.9;
Figure 2A). $\frac{1}{2}$

Hippocampus and subfield rCBF. Diazepam significantly reduced rCBF in the hippocampus by
7.8% (t(69)=-5.1, p_{FDR}<0.001), which did not differ between hemispheres (t(69)=0.9, p_{FDR} =0.366; Figure 2B). This effect was observed across all subfields: **CA1** 8.2% (condition: $t(69)=5.1$, $p_{fDR}<0.001$; condition*hemisphere: $t(69)=0.8$, $p_{fDR}=0.403$; Figure 2D), subiculum 8.6% (condition: $t(69)=-4.9$, $p_{FDR}<0.001$; condition*hemisphere: $t(69)=1.1$, $p_{FDR}=0.303$; Figure 2E), and CA4/DG 8.7% (condition: $t(69)=-4.7$, $p_{FDR}<0.001$; condition*hemisphere: $t(69)=0.8$, $p=0.405$; Figure 2F). These results did not change after controlling for global CBF, sex, order of scan conditions, or number of days between scans (Supplementary Table 1). S order of scan conditions, or number of days between scans S or S or S or S . Table 1). The conditions of S or S or

CHR-P diazepam vs. HC

Global CBF. There was no significant difference (F(1,42)=0.5, p_{FDR}=0.209) in mean total brain
GM CBF in CHR-P in the diazepam condition (56.3±12.7) compared to HC (54.3±10.9; Figure GM CBF in CHR-P in the diazepam condition (56.3±12.7) compared to HC (54.3±10.9; Figure
2A). 2A).
Hippocampus and subfield rCBF. There was no significant difference in rCBF between CHR-P

under diazepam compared to HC in the hippocampus $(F(1,41)=0.4, p_{FDR}=0.204; Figure 2B)$ CA1 ($F(1,41)=0.9$, $p_{FDR}=0.153$; Figure 2D), subiculum ($F(1,41)=0.8$, $p_{FDR}=0.272$; Figure 2E), or CA1 (F(1,41)=0.9, p_{FDR}=0.153; Figure 2D), subiculum (F(1,41)=0.8, p_{FDR}=0.272; Figure 2E), or
CA4/DG (F(1,41)=0.263, p_{FDR}=0.201; Figure 2F). C_A 4/DG ($C_{1,4,4,1}$ -0.203, ρ_{FDR} -0.201, Figure 2F).

Exploratory/supplementary analyses

Voxel-wise grey matter rCBF analysis

CHR-P placebo vs. HC. Several cortical regions showed increases (e.g., inferior/dorsolateral
frontal gyrus and temporal pole, p_{FDR}<0.05) and decreases (e.g., inferior parietal and middle occipital gyrus, p_{FDR}<0.05) in rCBF in the CHR-P placebo condition compared to HC (Supplementary Figure 1; Supplementary Table 2). $S = \frac{1}{2}$ Supplementary $F = \frac{1}{2}$.

CHR-P diazepam vs. CHR-P placebo. There was a global pattern of reduced rCBF under the
diazepam compared to placebo condition across cortical and subcortical areas (Figure 3; Supplementary Table 3). Peak voxels (all $p_{fDR} < 0.01$) were located in temporal (temporal pole, parahippocampal gyrus, hippocampus, amygdala, middle temporal gyrus), parietal (pre/post central gyrus, middle cingulate), frontal (dorsolateral prefrontal cortex (PFC), ventromedial orbitofrontal cortex, insula, superior frontal gyrus), and occipital (lingual gyrus, occipital gyrus, cuneus) regions, cerebellum, and subcortical regions (thalamus, putamen, caudate, gyrus, cuneus, cuneus) regions, cune $\frac{1}{2}$ regions (that regions $\frac{1}{2}$ regions (that regions $\frac{1}{2}$ regions (that regions $\frac{1}{2}$ regions $\frac{1}{2}$ regions (that regions $\frac{1}{2}$ regions $\frac{1}{2}$ regions $\$

َ ,
Clinical characteristics and hippocampal rCBF change

Exploratory analyses revealed significant associations between baseline positive symptoms
severity/social functioning and change in hippocampal rCBF, such that higher baseline positive symptom severity (r=0.494, p=0.014; Figure 4A) and poorer social functioning (r=-0.416, $p=0.043$; Figure 4D) were associated with less reduction in hippocampal rCBF following diazepam vs. placebo. Removal of outliers strengthened these correlations (positive symptoms: $r=0.598$, $p=0.003$; social functioning: $r=.0.538$, $p=0.008$). There were no significant correlations between negative symptoms ($r=-0.188$, $p=0.415$; Figure 4B), cognitive symptoms ($r=0.114$, $p=0.641$; Figure 4C), role functioning ($r=-0.106$, $p=0.623$; Figure 4E), anxiety ($r=-0.217$, $p=0.333$; Figure 4F) or depression symptoms ($r=-0.155$, $p=0.501$; Figure 4G) and diazepam-induced change in whole hippocampal rCBF. Most of these results remained unchanged when adding global CBF as covariate (Supplementary Table 4). remained unchanged when adding global CBF as covariate (Supplementary Table 4).

Discussion (1352 words)

In our sample, hippocampal rCBF was significantly higher in CHR-P individuals under placebo significantly reduced and normalised to HC levels. This effect was evident across all hippocampal subfields investigated. Our findings in CHR-P individuals present forwardtranslation of mechanistic evidence from psychosis-relevant preclinical studies, lending new empirical support to the notion that regulating hippocampal hyperactivity through GABAenhancing compounds may be a potential therapeutic strategy in early psychosis. enhancing compounds may be a potential therapeutic strategy in early psychosis. The system of the system of the
Therapeutic strategy in early psychosis. The system of the system of the system of the system of the system of

 $\ddot{}$ Our finding of elevated hippocampal rCBF in CHR-P (under placebo) compared to HC is
consistent with previous rCBF or rCBV studies^{33–37}. We also identified a global increase in CBF, as previously reported³⁵. Nonetheless, hippocampal rCBF elevation remained significant after controlling for global CBF, suggesting that the hippocampus is particularly hyperactive in CHR-P individuals compared to controls. We hypothesised that elevations in hippocampal rCBF would be most pronounced in the CA1 subfield, based on a recent rCBV study in CHR-P individuals³⁷ and current models of psychosis pathophysiology⁷. However, we observed individuals" and current models of psychosis pathophysiology'. However, we observed
similarly elevated rCBF across all subfields (CA1, subiculum, and CA4/DG). We sampled rCBF across the whole length of the hippocampus, whereas the previous study³⁷ only focussed on anterior regions of hippocampal subfields, and it is possible that posterior sections of subfields may also be hyperactive. Indeed, prior studies reported peak increases in rCBF in CHR-P individuals within the body/tail of the hippocampus³⁵, a finding which was replicated in an independent cohort of CHR-P individuals³⁶ and in high schizotypy⁴⁸. Additionally, in contrast to the previous study³⁷, our study used rCBF which is more tightly coupled to contrast to the previous study^s', our study used rCBF which is more tightly coupled to
neuronal activity than rCBV⁶⁵, sampled in native vs. common space thereby circumventing neuronal activity than rCBV°°, sampled in native vs. common space thereby circumventing
-

normalisation errors^{ss}, and sampled with individual hippocampal/subfield masks thereby
affording higher accuracy given the neuroanatomical diversity among individuals⁶⁷. affording higher accuracy given the neuroanatomical diversity among individuals67.

 $\overline{1}$ In line with our second hypothesis, diazepam significantly reduced hippocampal and subfield
rCBF vs. placebo in CHR-P individuals, to the extent that rCBF was no longer significantly different to HC. This finding is consistent with predictions from preclinical studies²⁹. In the MAM rodent model, hippocampal hyperactivity is associated with a local reduction of GABAergic PV+ interneurons²⁴⁻²⁶, and increasing GABAergic inhibition by hippocampal infusion of an α 5-GABA_A PAM normalises hippocampal hyperactivity²⁹. Importantly, repeated oral administration of diazepam in peripubertal MAM rats prevents local PV+ interneuron $loss³¹$ and the emergence of a hyperdopaminergic state at adulthood³⁰. A likely mechanism is downregulation of amygdala-hippocampal overdrive, which causes PV+ interneuron loss in the hippocampus and, consequently, hippocampal hyperactivity. This is supported by findings that direct hippocampal infusion of the benzodiazepine midazolam normalises increased dopamine neuron firing in the VTA of adult MAM rats²⁸. Our finding of diazepaminduced reductions in rCBF across all hippocampal subfields aligns with the pharmacology of benzodiazepines and GABA_A receptor distribution^{45,68}. Benzodiazepines are PAMs of the GABA_A receptor via the benzodiazepine site, which lies adjacent to α 1-3/ α 5 receptor subunits⁶⁹. Whilst GABA_A receptors are expressed on several cell types and sites⁷⁰, most commonly benzodiazepine binding facilitates greater hyperpolarisation of post-synaptic glutamatergic pyramidal cells and reduced pyramidal cell firing⁶⁹. This is expected to result in reduced metabolic requirements and, therefore, reduced rCBF 71 . Although there are slight differences in the levels of α 1-3/ α 5 receptor subunits (and therefore benzodiazepine sites) differences in the levels of α1-3/α5 receptor subunits (and therefore benzodiazepine sites)
across hippocampal subfields⁶⁸, α1-3/α5-GABA_A receptors are highly expressed across the across hippocampal subfields⁶⁸, α1-3/α5-GABA_A receptors are highly expressed across the
expressed across the

hippocampus^{44,45}, and diazepam has comparably high affinity for them⁷². Additionally, as
hippocampal subfields are highly interconnected⁶⁹, it is intuitive that diazepam was associated with a similar magnitude of reduction in rCBF across subfields. associated with a similar magnitude of \mathcal{S}^{max} and \mathcal{S}^{max} and \mathcal{S}^{max}

 $\ddot{}$ Complementary voxel-wise analyses revealed rCBF reductions across multiple other cortical pre/post central gyrus and inferior frontal regions, which are the areas with the highest benzodiazepine receptor binding sites both in vivo and ex vivo⁴⁴, and receive projections from the hippocampus^{15,16}. Large rCBF reductions were also seen in the striatum, ventromedial PFC, and amygdala, which together with the hippocampus compose a corticolimbic-striatal circuit proposed to be central to the pathophysiology of psychosis¹⁹. The reductions in rCBF observed in further cortical regions (motor cortex, occipital cortex, thalamus, posterior cingulate cortex) may be related to the ubiquitous binding profile of benzodiazepines. For example, α 1- α 3 subunits show widespread cortical distribution and have been implicated in benzodiazepine-related side effects such as sedation and addiction⁷³. Conversely, α 5-GABA_A receptors are preferentially expressed in the hippocampus^{45,68}, and α 5-GABA_A agonism of which is not associated with such side effects⁷³. Furthermore, there is evidence implicating α 5 over α 1-3-GABA_A receptors in the pathophysiology of psychosis. PET studies in antipsychotic-free patients with schizophrenia using a α 5-GABA_A selective ligand ($\left[1^{11}C\right]$ -Ro15-4513) showed reduced binding in the hippocampus⁷⁴, and negative correlations with negative symptoms⁷⁵, whilst less specific α 1 h_1 _{2,5}-GABA_A ligands ($\left[\begin{matrix}1^{23} \\ 1^{-10} \\ 1^{-10} \\ 0 & 1^{-10} \\ 0 & 1^{-10} \\ 0 & 0 & 1\end{matrix}\right]$ and h_1 ¹ and h_2 is $\left[\begin{matrix}1^{20} \\ 1^{20} \\ 1^{-10} \\ 0 & 1\end{matrix}\right]$ and h_3 differences between people with a diagnosis of schizophrenia⁷⁶⁻⁷⁹, or CHR-P individuals⁸⁰, differences between people with a diagnosis of schizophrenia 76 79 , or CHR-P individuals $^{\circ\circ}$,
and healthy controls. In line with this, evidence from the MAM model shows i) α 5 but not and healthy controls. In line with this, evidence from the MAM model shows i) α5 but not
 $\frac{1}{2}$

 α 1-3-GABA_A receptors are reduced in the subiculum and CA1⁸¹, ii) overexpression of the α 5, but not α 1, subunit normalises hippocampal hyperactivity²⁷, and iii) an α 5-GABA_A PAM was able to normalise hippocampal hyperactivity²⁹ and attenuate dopamine neuron activity in the VTA to a greater extent that the non-specific benzodiazepine midazolam²⁸. Taken together, pharmacological agents with high selectivity for α 5-GABA_A receptors may be able to regulate hippocampal hyperactivity more specifically in psychosis while potentially avoiding some of the unwanted side effects of less-selective benzodiazepines. While several α5-GABA_A PAMs exist⁸², none have yet proceeded to clinical development for psychosis.

_{α5-GABA PAMs exist⁸², none have yet proceeded to clinical development for psychosis.}

|
| Finally, reductions in hippocampal rCBF under diazepam appeared to be smallest in CHR-P
participants with higher severity of positive symptoms and poorer social functioning. Current theories propose persistent hyperactivity (i.e., excessive glutamate release) in the hippocampus of CHR-P individuals can lead to atrophic processes of neuropil and PV+ inhibitory interneurons⁷. Therefore, diazepam may not be able to downregulate rCBF as inhibitory interneurons'. Therefore, diazepam may not be able to downregulate rCBF as
effectively in CHR-P individuals with a more severe clinical profile and who potentially have a greater degree of GABAergic interneuron dysfunction. However, interpretation of this finding is limited by low power for examining correlations between clinical and imaging variables, ان کی دی ہے۔
and differences in timing between clinical and CBF measurements (i.e., 1st and 2nd scan were and differences in timing between clinical and CBF measurements (i.e., 1st and 2nd scan were
~2 and ~6 weeks after the assessment visit). \mathcal{L}^2 and \mathcal{L}^2 and \mathcal{L}^2 assessment visit \mathcal{L}^2

 $\ddot{}$ Overall, this novel experimental medicine study presents first-in-human evidence of
successful down-regulation of hippocampal hyperactivity by pharmacological modulation of the GABAergic system in CHR-P individuals. We used a robust randomised, double-blind, placebo-controlled, crossover study design, with an adequately powered sample based on p lacebo-controlled, crossover study design, with an adequately powered sample based on

prior research determining that n=20 is needed for within-subject pharmacological ASL
studies⁸³. All participants were antipsychotic-naïve, avoiding the known effects of studies⁸⁹. All participants were antipsychotic-naïve, avoiding the known effects of
antipsychotics on rCBF or the GABAergic system^{84–86}. We used advanced computational antipsychotics on rCBF or the GABAergic system^{er oo}. We used advanced computational
neuroimaging methods to automatically segment the hippocampus into its subfields with neuroimaging methods to automatically segment the hippocampus into its subfields with
high accuracy, using the MAGeT Brain toolbox that outperforms popular competing methods⁵⁷. This high level of accuracy was maintained by sampling ROI rCBF in each participant's native space and conducting voxel-wise analyses in a study-specific common space. We used ASL, a highly suitable neuroimaging measure (e.g., compared to PET or magnetic resonance spectroscopy [MRS]) for investigating the effects of a GABAergic drug challenge on hippocampal function, given it is fully quantitative, non-invasive, has better challenge on the state on hippocampal function, $\frac{1}{2}$ is function. Spatial resolution and SNR compared to PET 83 , and higher test-retest reliability than GABA. spatial resolution and SNR compared to PET°°, and higher test-retest reliability than GABA
concentration measurement using MRS⁸⁷. concentration measurement using MRS⁸⁷.

 $\begin{array}{c} \hline \end{array}$ This study also has some limitations. Despite segmenting all hippocampal subfields, we
could not reliably sample and assess the smaller CA2/3 subfield due to the spatial resolution of ASL. Additionally, unlike the CHR-P group, the HC group were scanned in the absence of a placebo condition. It is possible that placebo administration or broader factors relating to participating in a pharmacological study may have impacted rCBF. participating in a pharmacological study may have impacted rCBF.

$\overline{}$ Conclusions

This study provides first evidence that a single dose of a non-specific GABA-enhancing drug
like diazepam can significantly reduce hippocampal and subfield hyperactivity in CHR-P individuals and normalise it to HC levels. Diazepam-associated reductions in rCBF were also observed in other cortico-limbic-striatal regions, supporting further investigation of whether observed in other cortico-limbic-striatal regions, supporting further investigation of whether

20

diazepam can modulate the function of this circuit in CHR-P individuals. Furthermore, the
results validate the use of ASL and native-space hippocampal and subfield sampling as viable biomarker endpoints for the development of more hippocampal-selective GABA-enhancing biomarker endpoints for the development of more hippocampal-selective GABA-enhancing compounds for psychosis.

Acknowledgements

We would like to thank all our participants who took the time to participate in this study, as
well as the OASIS clinical team members and the radiographers at the Centre for Neuroimaging Sciences. This is independent research funded by the Wellcome Trust & The Royal Society (grant number 202397/Z/16/Z to GM) and carried out at the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC). NRL is supported by an MRC DTP PhD studentship. LAJ is supported by an MRC Clinical Research Training Fellowship (MR/T028084/1). PFP is supported by the European Union funding within the MUR PNRR Extended Partnership initiative on Neuroscience and Neuropharmacology (Project no. PE00000006 CUP H93C22000660006 "MNESYS, A multiscale integrated approach to the study of the nervous system in health and disease"). TJR Is supported by an MRC Clinical Research Training Fellowship (MR/W015943/1). AAG is supported by the National Institute of Mental Health (USPHS MH57440). The views expressed are those of the authors and not necessarily those of the Wellcome Trust & The Royal Society, the NIHR, or the Department of Health and Social Care. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Accepted Author Manuscript version arising from this submission.

م
Data availability. Data will be made freely availa Data availability. Data will be made freely available upon publication
(10.6084/m9.figshare.24763839), including i) mean-rCBF-values-per-subject-per-ROI-per hemisphere per condition, and ii) coding scripts for the MRI preprocessing pipeline (run in Unix/shell) and generation of figures (run in R).

Author contributions. NRL: Methodology, Software, Formal analysis, Investigation, Data curation, Writing - original draft, Visualization, Project administration; Funding acquisition. curation, Writing – original draft, Visualization, Visycle administration, Calendary and Turking and Internati
AK: Investigation, Writing – review & editing, Project administration; GAD: Software, Formal AK: Investigation, Writing – review & editing, Project administration; GAD: Software, Formal

22

analysis, Writing – review & editing; SK: Investigation, Writing – review & editing; PBL:
Investigation, Writing – review & editing; LJ: Investigation, Writing – review & editing; TR: Investigation, Writing – review & editing; AD: Investigation, Writing – review & editing; **MAN:** Investigation, Writing – review & editing; CC: Investigation, Writing – review & editing; TA: Formal analysis, Writing – review & editing; FZ: Software, Resources, Writing – review & editing; TS: Resources, Writing – review & editing; ADM: Resources, Writing – review & editing; PFP: Resources, Writing – review & editing; $AAG:$ Writing – review & editing; SCRW: Resources, Writing – review & editing; PM: Conceptualization, Resources, Writing – review & editing; AE: Methodology, Writing – review & editing, Supervision; MMC: Software, Methodology, Writing – review & editing, Supervision; GM: Conceptualization, Methodology, Writing – review & editing, Supervision, Funding acquisition. Methodology, Writing – review & editing, Supervision, Funding acquisition.

Disclosures

GM has received consulting fees from Boehringer Ingelheim. AE has received consulting fees Alkermes, Newron, Takeda and Merck. SCRW has recently received research funding from Boehringer Ingelheim and GE Healthcare to perform investigator-led research. All other authors have no financial disclosures or conflicts of interest.

References

- 1. Fusar-Poli P. Integrated Mental Health Services for the Developmental Period (0 to 25
Years): A Critical Review of the Evidence. Front Psychiatry. 2019;10:355. doi: 10.3389/fpsyt. 2019.00355
- 2. McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry. 2008;7(3):148-156.
- 3. Davies C, Cipriani A, Ioannidis JPA, et al. Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. World Psychiatry. Published online
2018. doi:10.1002/wps.20526 interventions in psychosis: a network meta-analysis. Wo*rld Psychiatry.* Published online
2018. doi:10.1002/wps.20526
- 4. Devoe DJ, Farris MS, Townes P, Addington J. Interventions and Transition in Youth at Risk of Psychosis: A Systematic Review and Meta-Analyses. J Clin Psychiatry. 2020;81(3):9326.
doi:10.4088/JCP.17r12053 of Psychosis: A Systematic Review and Meta-Analyses. J Clin Psychiatry. 2020;81(3):9326.
doi:10.4088/JCP.17r12053
- 5. Fusar-Poli P, Davies C, Solmi M, et al. Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence). Front Psychiatry. 2019;10:764. doi:10.3389/fpsyt.2019.00764
- 6. Bosnjak Kuharic D, Kekin I, Hew J, Rojnic Kuzman M, Puljak L. Interventions for prodromal stage of psychosis. Cochrane Database of Systematic Reviews. Published online 2019. doi:10.1002/14651858.CD012236.pub2
- 7. Lieberman JA, Girgis RR, Brucato G, et al. Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. Molecular Psychiatry. Published online 2018. doi:10.1038/mp.2017.249
- 8. Knight S, McCutcheon R, Dwir D, et al. Hippocampal circuit dysfunction in psychosis. Transl Psychiatry. 2022;12(1):344. doi:10.1038/s41398-022-02115-5
- 9. Benes FM, Kwok EW, Vincent SL, Todtenkopf MS. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biological Psychiatry. 1998;44(2):88-97. doi:10.1016/S0006-3223(98)00138-3
- 10. Heckers S, Stone D, Walsh J, Shick J, Koul P, Benes FM. Differential Hippocampal Expression of Glutamic Acid Decarboxylase 65 and 67 Messenger RNA in Bipolar Disorder and Schizophrenia. Archives of General Psychiatry. 2002;59(6):521-529. doi:10.1001/archpsyc.59.6.521
- 11. Zhang ZJ, Reynolds GP. A selective decrease in the relative density of parvalbumin-
immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res. 2002;55(1-2):1-10. doi:10.1016/s0920-9964(01)00188-8 immunoreactive neurons in the impocampus in schizophrenia. Schizophr Res.
2002;55(1-2):1-10. doi:10.1016/s0920-9964(01)00188-8
- 12. Konradi C, Yang CK, Zimmerman EI, et al. Hippocampal interneurons are abnormal in schizophrenia. Schizophrenia Research. 2011;131(1):165-173. doi:10.1016/j.schres. 2011.06.007 doi:10.1016/j.schres.2011.06.007

- 13. Wang AY, Lohmann KM, Yang CK, et al. Bipolar disorder type 1 and schizophrenia are interneurons in the parahippocampal region. Acta Neuropathol. $2011;122(5):615-626$. doi: 10.1007/s00401-011-0881-4
- 14. Heckers S, Konradi C. GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophrenia Research. Published online 2015. doi: 10.1016/j.schres. 2014. 09.041
- 15. Cenguizca LA, Swanson LW. Spatial organization of direct hippocampal field CA1 axonal projections to the rest of the cerebral cortex. Brain Research Reviews. 2007;56(1):1-26. doi: 10.1016/j.brain resrev. 2007.05.002
- 16. Groenewegen HJ, der Zee EVV, te Kortschot A, Witter MP. Organization of the projections from the subiculum to the ventral striatum in the rat. A study using anterograde 16. The concrete generation, the Zee EVV, te Kortschot A, Witter MP. Organization of the projection
from the subiculum to the ventral striatum in the rat. A study using anterograde
transport of Phaseolus vulgaris leucoaggl from the substantial string in the ventral model in the value of panal string and regions.
transport of Phaseolus vulgaris leucoagglutinin. Neuroscience. 1987;23(1):103-1.
doi:10.1016/0306-4522(87)90275-2 doi: 10.1016/0306-4522(87)90275-2
- 17. Herman JP, Mueller NK. Role of the ventral subiculum in stress integration. Behavioural Brain Research. 2006;174(2):215-224. doi:10.1016/j.bbr.2006.05.035
- 18. Jay TM, Witter MP. Distribution of hippocampal CA1 and subicular efferents in the
prefrontal cortex of the rat studied by means of anterograde transport of Phaseolus prefrontal cortex of the rat studied by means of anterograde transport of Phaseolu
vulgaris-leucoagglutinin. Journal of Comparative Neurology. 1991;313(4):574-586. prefrom the rate of the rate of phase of anterograde transport of the rate rate
vulgaris-leucoagglutinin. Journal of Comparative Neurology. 1991;313(4):574-586.
doi:10.1002/cne.903130404 vulgaris-leucoagglutinin. Journal of Comparative Neurology. 1991;313(4):374-586.
doi:10.1002/cne.903130404 doi:10.1002/cne.903130404
19. Grace AA. Dysregulation of the dopamine system in the pathophysiology of
- schizophrenia and depression. Nature Reviews Neuroscience. Published online 2016.
doi:10.1038/nrn.2016.57 schizophrenia and depression. Nature Reviews Neuroscience. Published online 2016.
doi:10.1038/nrn.2016.57
- 20. Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. A Neurobehavioral Systems Analysis of Adult Rats Exposed to Methylazoxymethanol Acetate on E17: Implications for the Neuropathology of Schizophrenia. Biological Psychiatry. Published online 2006. doi: 10.1016/j.biopsych. 2006.01.003
- 21. Lodge DJ, Grace AA. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. Journal of Neuroscience. Published online 2007. doi:10.1523/JNEUROSCI.2847-07.2007
- 22. Lodge DJ, Grace AA. Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia. Neurotoxicity Research. Published online 2008. doi:10.1007/BF03033801
- 23. Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. 23. Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumin-containing interneurons is associated with diminished schinker, activity in an animal model of schizophrenia.
Journal of Neuroscience. Published online 2009. doi:10.1523/JNEUROSCI.5419-08.20
- 24. Gilani Al, Chohan MO, Inan M, et al. Interneuron precursor transplants in adult hippocampus reverse psychosis-relevant features in a mouse model of hippocampal hippocampus reverse psychosis-relevant features in a mouse model of hippocampal

disinhibition. Proc Natl Acad Sci U S A. 2014;111(20):7450-7455.
doi:10.1073/pnas.1316488111

- 25. Kiemes A, Serrano Navacerrada ME, Kim E, et al. Erbb4 Deletion From Inhibitory Interneurons Causes Psychosis-Relevant Neuroimaging Phenotypes. Schizophrenia Bulletin. Published online December 27, 2022:sbac192. doi:10.1093/schbul/sbac192
- 26. Boley AM, Perez SM, Lodge DJ. A fundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia. Schizophrenia Research. Published online 2014. doi:10.1016/j.schres.2014.05.005
- 27. Donegan JJ, Boley AM, Yamaguchi J, Toney GM, Lodge DJ. Modulation of extrasynaptic GABAA alpha 5 receptors in the ventral hippocampus normalizes physiological and behavioral deficits in a circuit specific manner. Nat Commun. 2019;10:2819. doi: 10.1038/s41467-019-10800-1
- 28. Perez SM, McCoy AM, Prevot TD, et al. Hippocampal α 5-GABAA Receptors Modulate
Dopamine Neuron Activity in the Rat Ventral Tegmental Area. *Biological Psychiatry* Dopamine Neuron Activity in the Rat Ventral Tegmental Area. *Biological Psychiatry*
G*lobal Open Science*. 2023;3(1):78-86. doi:10.1016/j.bpsgos.2021.12.010 Dopamine Neuron Activity in the Rat Ventral Tegmental Area. Biological Psychiatry
Global Open Science. 2023;3(1):78-86. doi:10.1016/j.bpsgos.2021.12.010
- 29. Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA. A novel α 5GABA a r-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology. Published online 2011. doi:10.1038/npp.2011.76
- 30. Du Y, Grace AA. Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia. Neuropsychopharmacology. Published online 2013. doi:10.1038/npp.2013.101
- 31. Du Y, Grace AA. Loss of parvalbumin in the hippocampus of MAM schizophrenia model
rats is attenuated by peripubertal diazepam. *International Journal of* rats is attenuated by peripubertal diazepam. *International Journal of*
Neuropsychopharmacology. Published online 2016. doi:10.1093/ijnp/pyw065 rats is attenuated by peripubertal diazepam. *International Journal of*
Neuropsychopharmacology. Published online 2016. doi:10.1093/ijnp.
- 32. Du Y, Grace AA. Amygdala Hyperactivity in MAM Model of Schizophrenia is Normalized by Peripubertal Diazepam Administration. Neuropsychopharmacology. Published online
2016. doi:10.1038/npp.2016.42 by Peripubertal Diazepam Administration. Neuropsychopharmacology. Published online
2016. doi:10.1038/npp.2016.42 2016. doi:10.1038/npp.2016.42
33. Schobel SA, Lewandowski NM, Corcoran CM, et al. Differential targeting of the CA1
- subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Archives of General Psychiatry. Published online 2009. doi:10.1001/archgenpsychiatry. 2009.115
- 34. Schobel SA, Chaudhury NH, Khan UA, et al. Imaging Patients with Psychosis and a Mouse Model Establishes a Spreading Pattern of Hippocampal Dysfunction and Implicates Glutamate as a Driver. Neuron. Published online 2013. doi:10.1016/j.neuron. 2013.02.011 doi:10.1016/j.neuron.2013.02.011

- 35. Allen P, Chaddock CA, Egerton A, et al. Resting hyperperfusion of the hippocampus,
midbrain, and basal ganglia in people at high risk for psychosis. American Journal of $Psychiatry$. Published online 2016. doi:10.1176/appi.aip.2015.15040485
- 36. Allen P, Azis M, Modinos G, et al. Increased resting hippocampal and basal ganglia perfusion in people at ultra high risk for psychosis: Replication in a second cohort. Schizophrenia Bulletin. Published online 2018. doi:10.1093/schbul/sbx169
- 37. Provenzano FA, Guo J, Wall MM, et al. Hippocampal Pathology in Clinical High-Risk Patients and the Onset of Schizophrenia. Biol Psychiatry. 2020;87(3):234-242. doi: 10.1016/j.biopsych. 2019.09.022
- 38. Modinos G, Richter A, Egerton A, et al. Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes. Neuropsychopharmacology. 2021;46(8). doi:10.1038/s41386-021-01019-0
- 39. Modinos G, Simsek F, Azis M, et al. Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis. Neuropsychopharmacology. 2018;43(13):2652-2659. doi: 10.1038/s41386-017-0004-6
- 40. Mathew RJ, Wilson WH, Daniel DG. The effect of nonsedating doses of diazepam on regional cerebral blood flow. Biological Psychiatry. 1985;20(10):1109-1116. doi:10.1016/0006-3223(85)90010-1
- 41. Mathew RJ, Wilson WH. Evaluation of the effects of diazepam and an experimental anti-
anxiety drug on regional cerebral blood flow. Psychiatry Research: Neuroimaging. 1991;40(2):125-134. doi:10.1016/0925-4927(91)90004-A anxiety drug on regional cerebral blood flow. Psychiatry Research: Neuroimaging.
1991;40(2):125-134. doi:10.1016/0925-4927(91)90004-A
- 42. Matthew E, Andreason P, Pettigrew K, et al. Benzodiazepine receptors mediate regional blood flow changes in the living human brain. Proc Natl Acad Sci USA. 1995;92(7):2775-2779. doi:10.1073/pnas. 92.7.2775
- 43. Moresco RM, Tettamanti M, Gobbo C, et al. Acute effect of 3-(4-acetamido)-butyrril-
lorazepam (DDS2700) on brain function assessed by PET at rest and during attentive 13. More pam (DDS21. Pr) Tettamanti Microsoft of Apple Control Communication assessed by PET at rest and during attentive
tasks. Nuclear Medicine Communications. 2001;22(4):399.
- 44. Nørgaard M, Beliveau V, Ganz M, et al. A high-resolution in vivo atlas of the human brain's benzodiazepine binding site of GABAA receptors. Neuroimage. 2021;232:117878. binding binding site of the binding site of the binding site of 10.1016 /j. neuroimage. 2021;117878.
- 45. Sperk G, Schwarzer C, Tsunashima K, Fuchs K, Sieghart W. GABAA receptor subunits in the rat hippocampus I: Immunocytochemical distribution of 13 subunits. Neuroscience. 1997;80(4): 987-1000. doi: 10.1016/S0306-45 22 (97) 00146-2
- 46. Fusar-Poli P, Spencer T, De Micheli A, Curzi V, Nandha S, Mcguire P. Outreach and support in South-London (OASIS) 2001-2020: Twenty years of early detection, prognosis and
preventive care for young people at risk of psychosis. *European* preventive care for young people at risk of psychosis. *European*
Ne*uropsychopharmacology*. 2020;39:111-122. doi:10.1016/j.euroneuro.2020.08.002 preventive care for young people at risk of psychosis. *European*
Ne*uropsychopharmacology*. 2020;39:111-122. doi:10.1016/j.eu Neuropsychopharmacology. 2020;39:111-122. doi:10.1016/j.euroneuro.2020.08.002

- 47. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: The
Comprehensive Assessment of At-Risk Mental States. Australian and New Zealand Journal of Psychiatry. Published online 2005. doi:10.1111/j.1440-1614.2005.01714.x
- 48. Modinos G. Egerton A. McMullen K. et al. Increased resting perfusion of the hippocampus in high positive schizotypy: A pseudocontinuous arterial spin labeling study. Human Brain Mapping. Published online 2018. doi:10.1002/hbm.24231
- 49. Carrión RE, Auther AM, McLaughlin D, et al. The global functioning: Social and role
scales-further validation in a large sample of adolescents and young adults at clinical scales-further validation in a large sample of adolescents and young adults at clinic
high risk for psychosis. *Schizophrenia Bulletin*. 2019;45(4). doi:10.1093/schbul/sby1 scales-further validation in a large sample of adolescents and young adults at clinical
high risk for psychosis. Schizophrenia Bulletin. 2019;45(4). doi:10.1093/schbul/sby126
- 50. Hamilton M. Hamilton Anxiety Rating Scale (HAM-A). Journal of Medicine (Cincinnati). Published online 1959. doi:10.1145/363332.363339
- 51. HAMILTON M. A rating scale for depression. Journal of neurology, neurosurgery, and psychiatry. Published online 1960. doi:10.1136/jnnp.23.1.56
- 52. Velthorst E, Levine SZ, Henguet C, et al. To cut a short test even shorter: Reliability and validity of a brief assessment of intellectual ability in Schizophrenia - A control-case family study. Cognitive Neuropsychiatry. Published online 2013. doi:10.1080/13546805.2012.731390
- 53. Tombaugh TN. Trail Making Test A and B: Normative data stratified by age and education. 53. To the stage time term in the making test contribution to the entire the stratified by age and education.
Archives of Clinical Neuropsychology. Published online 2004. doi:10.1016/S0887-
6177(03)00039-8 Archives of Clinical Neuropsychology. Published online 2004. doi:10.1016/S0887-
6177(03)00039-8 6177(03)00039-8
- Effect of antacids and food. Clinical Pharmacology and Therapeutics. 1978;24(5). doi: 10.1002/cpt1978245600
- 55. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Transactions on Medical Imaging. 1998; 17(1): 87-97. doi: 10.1109/42.668698
- 56. Chakravarty MM, Steadman P, van Eede MC, et al. Performing label-fusion-based segmentation using multiple automatically generated templates. Hum Brain Mapp. 2012;34(10):2635-2654. doi:10.1002/hbm.22092
- 57. Pipitone J, Park MTM, Winterburn J, et al. Multi-atlas segmentation of the whole
hippocampus and subfields using multiple automatically generated templates. hippocampus and subfields using multiple automatically generated templates.
NeuroImage. 2014;101:494-512. doi:10.1016/j.neuroimage.2014.04.054 https://www.factbook.com/product/industrially/generated templates.html
Neurolmage. 2014;101:494-512. doi:10.1016/j.neuroimage.2014.04.054
- 58. Winterburn JL, Pruessner JC, Chavez S, et al. A novel in vivo atlas of human hippocampal subfields using high-resolution 3T magnetic resonance imaging. Neurolmage. 2013;74:254-265. doi:10.1016/j.neuroimage. 2013.02.003 2013;74:254-265. doi:10.1016/j.neuroimage.2013.02.003

- 59. Lindner T, Bolar DS, Achten E, et al. Current state and guidance on arterial spin labeling
perfusion MRI in clinical neuroimaging. Magnetic Resonance in Medicine. 2023;89(5):2024-2047. doi:10.1002/mrm.29572
- 60. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B
(Methodological). 1995;57(1):289-300. doi:10.1111/j.2517-6161.1995.tb02031.x Approach to Multiple Testing. Journal by the Royal Statistical Society: Series B
(Methodological). 1995;57(1):289-300. doi:10.1111/j.2517-6161.1995.tb0203
- 61. Zubieta JK, Heitzeg MM, Xu Y, et al. Regional Cerebral Blood Flow Responses to Smoking in Tobacco Smokers After Overnight Abstinence. AJP. 2005;162(3):567-577. doi: 10.1176/appi. ajp. 162.3.567
- 62. Niu X, Guo Y, Chang Z, et al. The correlation between changes in gray matter microstructure and cerebral blood flow in Alzheimer's disease. Front Aging Neurosci. 2023;15:1205838. doi:10.3389/fnagi.2023.1205838
- 63. Silva MA. Development of the WAIS-III: A Brief Overview, History, and Description.
Published online 2008. For Mar Development of the WAIS-III: A Brief Overview, History, A Brief Overview, History, and Description. History, and Development of the WAIS-III: A British of the WAIS-III: A British of the WAIS-III: A British of the W
- 64. Oduola S, Das-Munshi J, Bourque F, et al. Change in incidence rates for psychosis in
different ethnic groups in south London: findings from the Clinical Record Interactive different ethnic groups in south London: findings from the Clinical Record Interactiv
Search-First Episode Psychosis (CRIS-FEP) study. *Psychological Medicine*. 2021;51(2) different ethnic groups in south London: findings from the Clinical Record Interactive
Search-First Episode Psychosis (CRIS-FEP) study. *Psychological Medicine*. 2021;51(2):3
309. doi:10.1017/S0033291719003234 309. doi:10.1017/S0033291719003234
- 65. Hyder DSF, Sanganahalli B, Herman P, et al. Neurovascular and Neurometabolic Couplings in Dynamic Calibrated fMRI: Transient Oxidative Neuroenergetics for Block-
Design and Event-Related Paradigms. Frontiers in Neuroenergetics. 2010;2. Accessed October 26, 2023. https://www.frontiersin.org/articles/10.3389/fnene.2010.00018 Design and Event-Related Paradigms. Frontiers in Neuroenergetics. 2010, 2. Accessed
October 26, 2023. https://www.frontiersin.org/articles/10.3389/fnene.2010.00018
- 66. Robbins S, Evans AC, Collins DL, Whitesides S. Tuning and comparing spatial normalization methods. Medical Image Analysis. 2004;8(3):311-323. doi: 10.1016/j.media. 2004. 06. 009
- 67. Yang Q, Cai S, Chen G, et al. Fine scale hippocampus morphology variation cross 552 healthy subjects from age 20 to 80. Front Neurosci. 2023;17:1162096. doi: 10.3389/fnins .2023.1162096
- 68. Hörtnagl H, Tasan RO, Wieselthaler A, Kirchmair E, Sieghart W, Sperk G. Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain. Meuroscience. 2013;236:345-372. doi:10.1016/j.neuroscience.2013.01.008
- 69. Engin E, Benham RS, Rudolph U. An Emerging Circuit Pharmacology of GABAA Receptors. Trends Pharmacol Sci. 2018;39(8):710-732. doi:10.1016/j.tips.2018.04.003
- 70. Kullmann DM, Ruiz A, Rusakov DM, Scott R, Semyanov A, Walker MC. Presynaptic, extrasynaptic and axonal GABAA receptors in the CNS: where and why? Prog Biophys extrasynaptic and axonal GABAA receptors in the CNS: where and why? Prog Biophys
Mol Biol. 2005;87(1):33-46. doi:10.1016/j.pbiomolbio.2004.06.003 Mol Biol. 2005;87(1):33-46. doi:10.1016/j.pbiomolbio.2004.06.003

- 71. Venkat P, Chopp M, Chen J. New insights into coupling and uncoupling of cerebral blood
flow and metabolism in the brain. *Croat Med J.* 2016;57(3):223-228. doi: 10.3325/cmj. 2016. 57. 223
- 72. Möhler H. Okada T. Benzodiazepine Receptor: Demonstration in the Central Nervous System. Science. 1977;198(4319):849-851. doi:10.1126/science.918669
- 73. Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. *Nat Rev Drug Discov*. 2011;10(9):685-697.
doi:10.1038/nrd3502 GABAA receptor subtypes. Nat Rev Drug Discov. 2011;10(9):685-697.
doi:10.1038/nrd3502 doi:10.1038/nrd3502
-
:74. Marques TR, Ashok AH, Angelescu I, et al. GABA-A receptor differences in schizophrenia
- a positron emission tomography study using [11C]Ro154513. Molecular Psychiatry. 2021;26(6):2616. doi:10.1038/s41380-020-0711-y
- 75. Asai Y, Takano A, Ito H, et al. GABAA/Benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for α 5 subunit. Schizophrenia Research. 2008;99(1):333-340. doi:10.1016/j.schres.2007.10.014
- 76. Busatto GF, Pilowsky LS, Costa DC, et al. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am J Psychiatry. 1997;154(1):56-63. doi:10.1176/ajp.154.1.56
- 77. Abi-Dargham A, Laruelle M, Krystal J, et al. No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology. 1999;20(6):650-661. doi: 10.1016/S0893-133X(98)00107-9
- 78. Lee JS, Lee JD, Park HJ, et al. Is the GABA System Related to the Social Competence Improvement Effect of Aripiprazole? An (18)F-Fluoroflumazenil PET Study. Psychiatry Investig. 2013;10(1):75-80. doi:10.4306/pi.2013.10.1.75
- 79. Frankle WG, Cho RY, Prasad KM, et al. In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients. Am J Psychiatry. 2015;172(11):1148-1159. doi: 10.1176/appi. ajp. 2015. 14081031
- 80. Kang JI, Park HJ, Kim SJ, et al. Reduced Binding Potential of GABA-A/Benzodiazepine Receptors in Individuals at Ultra-high Risk for Psychosis: An [18 F]-Fluoroflumazenil Positron Emission Tomography Study. Schizophrenia Bulletin. 2014;40(3):548-557. doi:10.1093/schbul/sbt052
- 81. Kiemes A, Gomes FV, Cash D, et al. GABAA and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for their behavioral correlates in the gestational methylazoxymethanol acetate model for
schizophrenia. Neuropsychopharmacol. 2022;47(3):687-695. doi:10.1038/s41386-021schizophrenia. *Neuropsychopharmacol*. 2022;47(3):687-695. doi:10.1038/s41386-021[.]
01213-0 schizophrenia. Neuropsychopharmacol. 2022;47(3):687-695. doi:10.1038/s41386-621-
01213-0
. 01213-0
82. Jacob TC. Neurobiology and Therapeutic Potential of α5-GABA Type A Receptors. *Front*
- Mol Neurosci. 2019;12:179. doi:10.3389/fnmol.2019.00179 Mol Neurosci. 2019;12:179. doi:10.3389/fnmol.2019.00179

- 83. Wang DJJ, Chen Y, Fernández-Seara MA, Detre JA. Potentials and Challenges for Arterial
Spin Labeling in Pharmacological Magnetic Resonance Imaging. The Journal of Pharmacology and Experimental Therapeutics. $2011;337(2):359$. doi:10.1124/jpet.110.172577
- 84. Hawkins PCT, Wood TC, Vernon AC, et al. An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers. Hum Brain Mapp. 2017;39(1):319-331. doi:10.1002/hbm.23844
- 85. Gill KM, Cook JM, Poe MM, Grace AA. Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophrenia Bulletin. Published online 2014. doi:10.1093/schbul/sbt236
- 86. Peris-Yague A, Kiemes A, Cash D, et al. Region-specific and dose-specific effects of chronic haloperidol exposure on [3H]-flumazenil and [3H]-Ro15-4513 GABAA receptor binding sites in the rat brain. Eur Neuropsychopharmacol. 2020;41:106-117. doi: 10.1016/j.euroneuro. 2020. 10.004
- 87. Murphy K, Harris AD, Diukova A, et al. Pulsed arterial spin labeling perfusion imaging at 3
T: estimating the number of subjects required in common designs of clinical trials. 888. Murphy Myrrams AD, Diumonic Advisor arterial spin labeling perfusion imaging at 3
T: estimating the number of subjects required in common designs of clinical trials.
Magnetic Resonance Imaging. 2011;29(10):1382-1389. Magnetic Resonance Imaging. 2011;29(10):1382-1389. doi:10.1016/j.mri.2011.02.
.
- 88. Liang P, Xu Y, Lan F, Ma D, Li K. Decreased Cerebral Blood Flow in Mesial Thalamus and Precuneus/PCC during Midazolam Induced Sedation Assessed with ASL. Neuroinform. 2018;16(3):403-410. doi:10.1007/s12021-018-9368-y 2018;16(3):403-410. doi:10.1007/s12021-018-9368-y

Table and Figure Legends

Table 1. Demographic and clinical characteristics.

CAARMS: comprehensive assessment of at-risk mental states; CHR-P: clinical high-risk for psychosis; HC: healthy control; IQ: intelligent quotient; WAIS: WAIS: WAIS: WAIS: WAIS: WAIS: WAIS: WAIS: WAIS: WA
scale.

 $\overline{1}$ **Figure 1. ASL preprocessing and analysis pipeline. (A)** Diagram showing pipeline for region-
of-interest analysis. T1 images were preprocessed (1) and run through the MAGeT Brain toolbox (2), generating masks for grey matter, whole hippocampus, and hippocampal subfields. Using T1->T2->PD transformations calculated from registration (3 & 4), these masks were resampled (5) to CBF space (single resampling step) to allow for sampling of rCBF in native space (6). (B) Demonstration of optimum registration between CBF map, masks, and T1 images. (C) Schematic showing steps for voxel-wise analysis for CHR-P placebo vs. diazepam. A study-specific template was generated (1) from participant-averages (averaged structural scans from both drug conditions), and the CBF maps were resampled (2) to common space (single resampling step calculated from PD->T2->T1->template transformations/deformations).

hipp: hippocampus; PD: proton density; rCBF: regional cerebral blood flow; ROI: region-ofhipp: hippocampus; PD: proton density; rCBF: regional cerebral blood flow; ROI: region-of-

 $\overline{1}$ Figure 2. Region-of-interest rCBF findings. Absolute rCBF for HC and CHR-P participants
(under placebo and diazepam) for (A) total grey matter, (B) hippocampus, and (C) (under placebo and diazepam) for (A) total grey matter, (B) imppocampus, and (C)
hippocampus subfields, including (D) CA1, (E) subiculum, and (F) CA4/DG. hippocampus subfields, including (D) CA1, (E) subiculum, and (F) CA4/DG.

 32

CHR-P: clinical high-risk for psychosis; DG: dentate gyrus; rCBF: regional cerebral blood flow
ns = non-significant; * < 0.05; *** < 0.001. ns \mathbf{r} . The significant; $\mathbf{r} = \mathbf{r}$

 $\overline{1}$ **Figure 3. Voxel-wise grey matter rCBF findings.** *T*-statistic map of drug condition (diazepam
vs. placebo) effect on grey matter rCBF at the whole-brain level in CHR-P individuals from voxel-wise linear mixed effects models, thresholded and displayed at 5% FDR. Peak regions with t-statistic > 5 have been labelled. Colour bars denote t-statistics which reflect 5% FDR threshold (i.e., \pm 2.498) and less (i.e., up to \pm 6.68) for both contrasts (diazepam < placebo in blue/green and placebo < diazepam in yellow/red). N.B. there were no significant voxels at 5% FDR threshold for placebo < diazepam.

DLPFC: dorsolateral prefrontal cortex; MCC: middle cingulate cortex; NAc: nucleus accumbens; OFC: orbitofrontal cortex; rCBF: regional cerebral blood flow accumbens; α orbitofrontal cortex; regional cortex; regional blood flow α

 $\overline{1}$ Figure 4. Association between baseline clinical characteristics and diazepam-induced hippocampal rCBF changes. Pearson correlations between change in absolute hippocampal
rCBF by diazepam vs. placebo and baseline clinical characteristics (at assessment visit): (A) positive symptoms, (B) negative symptoms, (C) cognitive functioning, (D) social functioning, (E) role functioning, (F) anxiety symptoms, and (G) depression symptoms.

N.B. for panels D & E a higher score denotes less impairment, whilst for all other panels a higher score/time denotes higher symptom severity. Shaded light green areas reflect 95% higher score/time denotes *higher symptom severity*. Shaded light green areas reflect 95%
confidence intervals.

confidence intervals.
rCBF: regional cerebral blood flow. rCBF: regional cerebral blood flow.

Table 1. Demographic and clinical characteristics

 $\ddot{}$ CAARMS: comprehensive assessment of at-risk mental states; CHR-P: clinical high-risk for psychosis; HC: healthy control; IQ: intelligent quotient; WAIS: Weschler adult intelligence scale

B Labels in CBF space for ROI analysis

